L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L- asparaginase as first exposure

Annals of Oncology

Volumn 11, Issue 2, 2000, Pages 189-193

  Rizzari, C ^a   Zucchetti, M ^b   Conter, V ^a   Diomede, L ^b   Bruno, A ^b   Gavazzi, L ^a   Paganini, M ^b   Sparano, P ^a   Lo Nigro, L ^c   Arico M ^d   Milani, M ^a   D'Incalci, M ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

ALL; Childhood; L asparaginase; L asparagine

Indexed keywords

ASPARAGINASE; ASPARAGINE; CYTARABINE; DAUNORUBICIN; MEDAC; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CEREBROSPINAL FLUID; CHILDHOOD LEUKEMIA; DRUG EFFICACY; ENZYME ACTIVITY; ERWINIA; ESCHERICHIA COLI; PLASMA; PRIORITY JOURNAL; PROTEIN DEPLETION;

EID: 17544399852     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008368916800     Document Type: Article

References (23)

1. Asselin BL, Ryan D, Frantz CN et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989; 49 (15): 4363-8.
2. Asselin BL, Whitin JC, Coppola DJ et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-6.
3. Gentili D, Conter V. Rizzari C et al. L-asparagine depletion in plasma and cerebrospinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol 1996; 7: 725-30.
4. Turnell DC, Cooper JDH. Rapid assay for aminoacids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clin Chem 1982; 28: 527-31.
5. Sallan SE, Hitchcock-Bryan S, Gelber R et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983; 43: 5601-7.
6. Faller DR, Beardsley GP, Mikita T, Sallan SE. Prolonged asparagine (Asn) depletion after high dose asparaginase (HDA) therapy in childhood acute lymphoblastic leukemia (ALL). Proc Am Acad Cancer Res 1985; 26: 617a (Abstr).
7. Holland JF, Ohnuma T. Asparaginase and amino acids in cancer therapeutics. Cancer Treat Rep 1981; 65 (Suppl 4): 123-30.
8. Boos J, Nowak-Göttl U, Jürgens H et al. Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol 1995; 13: 2474-5.
9. Vieira Pinheiro JP, Ahlke E, Nowak-Göttl U et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999; 104: 313-20.
10. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukemia. Med Pediatr Oncol 1990; 18: 497-502.
11. Rizzari C, Conter V, D'Incalci M, Masera G. L-asparagine depletion: Another opinion. Ann Oncol 1997; 8: 204-6.
12. Otten J, Suciu S, Lutz P et al. The importance of L-asparaginase (A'ASE) in the treatment of acute lymphoblastic leukemia (ALL) in children: Results of the EORTC 58881 randomized phase III trial showing greater efficiency of Escherichia coli (E. coli) as compared with Erwinia (ERW) A'ASE. Blood 1996; 88 (10, Suppl I): 669 (Abstr).
13. Conter V, Aricò M, Valsecchi MG et al. Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AIEOP ALL 91 study. Haematologica 1998; 83: 791-9.
14. Frankel SR, Kurtzberg J, De Oliveira D et al. Toxicity and pharmacokinetics of PEG-asparaginase (PEG-ASP) in newly diagnosed adult acute lymphoblastic leukemia: CALGB 9511. Blood 1996; 88 (Suppl 1/1): 669 (Abstr).
15. Koerholz D, Brüeck M, Nürnberger W et al. Chemical and immunological characteristics of four different L-asparaginase preparations. Eur J Haematol 1989; 42: 417-24.
16. Capizzi R. Asparaginase. In Holland J. Fries H (eds): Cancer Medicine. Philadelphia: Lea & Febiger 1993; 796-805.
17. Cheung NV, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986; 8: 99-104.
18. Kurtzberg J, Asselin B, Poplack D et al. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc Am Assoc Cancer Res 1993; 34: 304 (Abstr).
19. Ahlke E, Nowak-Göttl U, Schülze-Westhoff P et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia. Br J Haematol 1997; 96: 675-81.
20. Liang D-C, Hung I-J, Yang C-P et al. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: A report from the Taiwan Pediatric Oncology Group, 1999; 13: 155-60.
21. Riccardi R, Holcenberg JS, Glaubinger DL et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981; 41: 4554-8.
22. Boos J, Werber J, Ahlke E et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Fur J Cancer 1996; 32A: 1544-50.
23. Woo MH, Hak LJ, Storm MC et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999; 17 (5): 1568-73.